Japan
Multiple myeloma treatment approved in Japan
May 21, 2025Market Access, Research and Development, Sales and Marketing GSK, Japan, Oncology, Orphan Drug Designation (ODD), multiple myeloma
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and Welfare for the treatment of …
Japan approves Moderna & AstraZeneca COVID-19 vaccines
May 21, 2021Medical Communications COVID-19, Japan, Vaccine
A Japanese government panel has approved Moderna and AstraZeneca’s COVID-19 vaccines for use in adults, bringing the total number of …
Incyte biliary tract cancer treatment approved in Japan
March 23, 2021Manufacturing and Production EMA, Japan, oncology
The Japanese Ministry of Health, Labour, and Welfare (MHLW) have approved Incyte’s Pemazyre (pemigatinib) for the treatment of patients with …
Cabometyx scores Japanese approval for unresectable hepatocellular carcinoma patients following systemic therapy
November 30, 2020Sales and Marketing Cabometyx, Japan, Takeda
The Japanese Ministry of Health, Labor and Welfare has awarded approval to Takeda for Cabometyx (cabozantinib) as a treatment for …
Japan approves Astellas and FibroGen’s Evrenzo for chronic kidney disease patients currently not receiving dialysis
November 27, 2020Medical Communications, Sales and Marketing Astellas, Japan, fibrogen
Japan’s Ministry of Health, Labour and Welfare (MHLW) has passed approval for Astellas and FibroGen’s Evrenzo (roxadustat) in the treatment …
Takeda commits to deliver 50 million doses of Moderna’s COVID-19 vaccine in Japan
October 29, 2020Manufacturing and Production, Sales and Marketing COVID-19, Japan, Moderna, Takeda, Vaccine
Takeda has made a commitment with Japan’s Ministry of Health, Labor and Welfare (MHLW) to deliver 50 million doses of …
Japan approves Gilead and Eisai’s Jyseleca for rheumatoid arthritis
September 25, 2020Medical Communications, Sales and Marketing Eisai, Gilead, Japan, Jyseleca
Gilead and Eisai have secured approval for their oral JAK1 preferential inhibitor Jyseleca (filgotinib) from the Japanese Ministry of Health, …
AstraZeneca scores Japanese approval for Imfinzi combo in extensive-stage small cell lung cancer
August 21, 2020Medical Communications, Sales and Marketing AstraZeneca, Imfinzi, Japan
AstraZeneca’s Imfinzi (durvalumab) has secured approval in Japan for the treatment of extensive-stage small cell lung cancer when combined with etoposide and …
Japan reserves 120m doses of BioNTech’s COVID-19 vaccine
July 31, 2020Manufacturing and Production, Medical Communications BioNTech, COVID-19, Japan, Vaccine, pharma
Japan’s Ministry of Health, Labour and Welfare (MHLW) has sealed a deal with Pfizer and BioNTech to secure 120 million …
Takeda poised to cut sales jobs in Japan as restructuring continues
July 29, 2020Medical Communications, Research and Development, Sales and Marketing Japan, Takeda, job cuts
Japan’s biggest drug firm Takeda is said to be mulling plans to cut back its sales operations with a new …
Fujifilm to begin clinical trials testing Avigan in COVID-19 patients in Kuwait
July 21, 2020Manufacturing and Production COVID-19, Fujifilm, Japan, avigan, coronavirus
Fujifilm will begin clinical trials investigating the effectiveness of Avigan in treating coronavirus patients in Kuwait. The trials will be …
Japan authorises exceptional approval of Gilead’s remdesivir for severe COVID-19
May 12, 2020Manufacturing and Production, Sales and Marketing COVID-19, Gilead, Japan, coronavirus, pharma, remdesivir
Remdesivir, perhaps the leading hope in the race against COVID-19, has secured approval from Japan’s Ministry of Health, Labour and …
First for Japan with the approval of AstraZeneca’s Lokelma in hyperkalaemia
March 26, 2020Sales and Marketing AstraZeneca, Astra|Zeneca, Japan, Lokelma, hyperkalaemia, pharma
Japan’s Ministry of Health, Labour and Welfare has awarded approval to AstraZeneca’s Lokelma for the treatment of hyerkalaemia, marking the …
Japan grants orphan drug designation to Lynparza for BRCA+ unresectable pancreatic cancer
March 19, 2020Research and Development, Sales and Marketing AstraZeneca, Japan, lynparza, pharma
AstraZeneca has confirmed that its PARP inhibitor Lynparza (olaparib) has been awarded orphan drug designation in Japan for the maintenance …
